Navigation Links
Project to capture and interrogate single cancer cells wins innovator award

HOUSTON From a single cell gone bad, cancer evolves into an increasingly complex tumor built of a variety of normal cells and diverse malignant cells, some of which escape to create dangerous colonies in other organs, further jumbling the treatment picture.

Nicholas Navin, Ph.D., an assistant professor in The University of Texas MD Anderson Cancer Center Department of Genetics, believes the key to sorting out this cellular chaos is by identifying important mutations in single tumor cells at various stages of the cancer's development.

Successfully analyzing differences in active mutations among cells would help researchers understand, map and eventually block the lethal path to metastasis spread of the primary cancer to other organs.

"The genetic diversity of tumor cells inhibits our understanding of metastasis. Single-cell sequencing will allow us to detail the genetic heterogeneity and trace the cell's lineage as mutations allow the cell to escape the primary tumor site, form a circulating cell and then seeds metastasis," Navin said. "Using genetic markers, we can reconstruct this evolutionary process."

The Damon Runyon Cancer Research Foundation wants Navin to test his idea, naming him the Nadia's Gift Foundation Innovator, one of its 2013 Damon Runyon-Rachleff Innovation Awards, providing $150,000 a year for three years.

Potential to predict metastasis, treatment response

Navin is one of seven early career scientists chosen for innovation awards because their projects have the potential to significantly improve prevention, diagnosis and treatment of cancer. The foundation announcement notes the innovation awards are for "cancer research by exceptionally creative thinkers with "high-risk/high-reward" ideas who lack sufficient preliminary data to obtain traditional funding."

The foundation noted that Navin's method "will have myriad clinical applications, which have prognostic value in predicting invasion, metastasis, survival and response to chemotherapy."

Navin is grateful to the foundation for support of the project, which he agrees is high-risk, high-reward because it aims to break new ground in the genomic analysis of cancer.

First, he must develop tools to reliably isolate individual cancer cells and identify mutations in all of the genes that encode proteins. Then he will apply single-cell gene sequencing to triple-negative breast cancer, the most lethal form of the disease.

Develop tools, apply them to triple-negative breast cancer

"Most of the tools we have now operate on bulk tumor tissue samples, which include normal supportive cells, or stroma, and immune system cells as well as cancer cells, which have different genetic mutations," Navin said. "So when we analyze tissue in bulk, we find the average genetic signal of the tumor. What you miss are the rare cells that may be most malignant."

Identifying these cells is particularly important for those with triple-negative breast cancer, which does not have the three protein targets that make other breast cancers much more treatable.

"Triple-negative breast cancer is the most aggressive type, with lowest survival rates, the most intratumor genetic heterogeneity, and it metastasizes the most," Navin said. "So there's really a dire need to help these patients by developing new therapies to inhibit metastasis."

To sequence the full coding regions of each single cell, Navin's lab will isolate single cells that have naturally doubled their chromosome content. The cell will be dissolved and the DNA will be expanded from picogram (trillionth of a gram) to nanogram (billionth) quantities using whole-genome amplification. This will provide sufficient material to generate libraries for 'next-generation' sequencing on the Illumina platform.

From this data, the full set of coding mutations can be detected in each cancer cell and compared to trace the lineage of their evolution during metastasis.

The project also will examine fundamental issues in cancer metastasis. "In cancer biology there's a big question about whether cells metastasize early in the growth of the primary tumor or if that occurs after the tumor has grown to a large size," Navin said. "Another model proposes that tumor cells can travel back and forth between primary and metastatic tumor sites. We're interested in looking at and understanding those models in triple- negative breast cancer."


Contact: Scott Mervilloe
University of Texas M. D. Anderson Cancer Center

Related medicine news :

1. How the brains daily clock controls mood: A new project
2. Image share project gives patients and physicians anytime, anywhere access to medical images
3. Optogenetics project takes top NIDA Addiction Science Award
4. Leah Hoskins, F.I.L.M. Project Founder, Headed to Jail?
5. The W3 Project Receives Support from Doulton for Emergency Relief Efforts
6. Gene sequencing project identifies potential drug targets in common childhood brain tumor
7. Stanford Woods Institute for the Environment announces 2012 Environmental Venture Project awards
8. Reveals How Project CAP and Insurance Agoragate will Take Away Market Share from the Captive Insurance Carriers and give it back to the Independents
9. JHU Bioethics Institute receives PCORI pilot project award
10. UCLA-led project aimed at African American couples affected by HIV gets $2.5 million boost
11. COPD Foundation and BWH announces second phase of groundbreaking COPDGene project
Post Your Comments:
(Date:6/24/2016)... ... ... June 19, 2016 is World Sickle Cell Observance Day. In an effort to ... treatments, Serenity Recovery Center of Marne, Michigan, has issued a pain management ... (SCD) is a disorder of the red blood cells, which can cause episodes of ...
(Date:6/24/2016)... ... 2016 , ... The Pulmonary Hypertension Association (PHA) learned during ... two significant new grants to support its work to advance research and patient ... recognizing patients, medical professionals and scientists for their work in fighting pulmonary hypertension ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... for accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas of ... AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway ... call for a minimum wage raise to $12 an hour by 2020 and then adjusting ... restore the lost value of the minimum wage, assure the wage floor does not erode ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... the Clinical Decision Making in Emergency Medicine conference in Ponte Vedra Beach, FL. ... articles published in Emergency Medicine Practice and Pediatric Emergency Medicine Practice. ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... FRANCISCO, Calif. , June 24, 2016 /PRNewswire/ ... ), a biopharmaceutical company developing novel therapeutics for ... unmet needs, today announced the closing of its ... of common stock, at the public offering price ... in the offering were offered by GBT. GBT ...
(Date:6/24/2016)... Research and Markets has ... 2015-2025: Applications, Technologies, Forecasts" report to their ... Electronics, Smart Skin, Structural Health Monitoring, Composite Smart ... electronics involves electronic and/or electrical components and circuits ... structures such as vehicle bodies or conformally placed ...
(Date:6/24/2016)... , June 24, 2016  American Respiratory Labs (ARL), a ... now able to perform sophisticated lung assessments in patients, homes, thanks ... Inc. Patients are no longer limited to having ... PRO ® , ARL patients like Jeanne R. of ... the comfort of her own home. ...
Breaking Medicine Technology: